NVS
PFE
RLAY
A little good news for Relay
Relay Therapeutics finally got a clean-looking clinical readout to brag about: early Phase 2 data for zovegalisib in vascular anomalies showed lesion reduction, symptom relief, and a safety profile that could make longer-term treatment more believable than your average biotech moonshot.
As of the April 15 data cutoff, 60% of response-evaluable patients hit a volumetric response at the first MRI check after 12 weeks. That’s not a guarantee of future glory, but in biotech land it’s the kind of number that makes investors sit up in their chairs.
Why investors care
The company said:
- 95% of the 20 efficacy-assessed patients saw lesion reduction
- nearly all patients reported symptom improvement
- 89% of investigator global impression scores improved at week 12
- 79% of patient global impression scores improved
- pain-related symptoms got better in 71% of evaluated cases
That matters because rare vascular disorders are the kind of niche where a drug can quietly turn into a big-value asset if the data keep holding up. And because many patients had already tried Novartis’ Piqray or Pfizer’s Rapamune before entering the study, Relay can point to a population that’s not exactly easy-to-impress.
More than a one-trick pony?
Relay also said enrollment is continuing in expansion cohorts testing different doses in adults and adolescents. Meanwhile, zovegalisib is still being pushed in breast cancer, including the Phase 3 ReDiscover-2 trial in HR-positive, HER2-negative advanced breast cancer with PI3Kα mutations.
So yes, this is still a classic biotech balancing act: one promising readout, several moving parts, and a stock that can sprint on optimism faster than most companies can print a slide deck. Big picture: if the next round of data stays friendly, zovegalisib could become a much more important story for Relay than just another pipeline footnote.